Board Member
Ptc Therapeutics, Inc. (PTCT)Equibles does not estimate personal net worth.
Get an email with a short summary when Ptc Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get PTCT alertsDr. Matthew B. Klein is recorded as CEO and Board Member at Ptc Therapeutics, Inc. (PTCT) since March 22, 2023. Ptc Therapeutics, Inc. reported in an 8-K filed April 18, 2023 that Dr. Matthew B. Klein was appointed Chief Executive Officer and President, effective March 22, 2023. Dr. Matthew B. Klein has spoken on 1 earnings call across 1 company, most recently for Ptc Therapeutics, Inc. on April 28, 2026. Ptc Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Ptc Therapeutics, Inc. includes Matthew B. Klein (CEO and Board Member), Matthew Klein (CEO and Board Member), Michael Schmertzler (CFO) and 7 others.
“The Agreement provides that Dr. Klein will be entitled to receive an annual base salary at the rate of $788,000, effective as of March 22, 2023, the date he was appointed Chief Executive Officer and President of the Company, and will have a target annual bonus opportunity of 75% of his annual base salary, in each case subject to adjustment.”
“We had a record quarter of product revenue led by the continued strong momentum of the Suppliance launch, as well as contributions from our mature products. First quarter total revenue was $273 million, including $226 million of product revenue.”
2023-03-22–present
2023-03-22–present
Biotechnology · Healthcare
CEO, Board Member
2023-03-22–present
